GSK vet Ja­son Gard­ner takes the helm of Ma­gen­ta, emerg­ing from stealth with a $48.5M round

Ja­son Gard­ner, Ma­gen­ta CEO. Jen Ran­dall Pho­tog­ra­phy.

Ja­son Gard­ner re­turned to his old stomp­ing grounds in Cam­bridge, MA back in the fall of 2014 with a mis­sion to hunt up new col­lab­o­ra­tions for the phar­ma gi­ant Glax­o­SmithK­line. He’s stay­ing on as CEO of an up­start biotech which is now com­ing out of stealth mode with a new plat­form tech un­der con­struc­tion for stem cell trans­plants. And he’s build­ing it with some of the top sci­en­tif­ic hands in the field.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.